Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06432894

Performance Evaluation of ANI in Patients Under General Anesthesia With Remimazolam

Performance Evaluation of Analgesia Nociception Index (ANI) in Patients Under General Anaesthesia With Remimazolam: a Prospective Observational Study

Status
Recruiting
Phase
Study type
Observational
Enrollment
30 (estimated)
Sponsor
Catholic Kwandong University · Academic / Other
Sex
All
Age
20 Years – 79 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine whether Analgesia Nociception Index (ANI) can effectively reduce the dose of opioid in patients who underwent general anesthesia using remimazolam.

Conditions

Interventions

TypeNameDescription
COMBINATION_PRODUCTAnalgesia Nociception Index, remimazolamThe purpose of this study is to determine the validity of ANI in patients undergoing surgery with remifentanil and remimazolam. During this study, remimazolam infusion rate is determined by the pharmacopoeia. Remifentanil infusion rate is determined based on the patient's vital signs, systemic status and pain levels. And remifentanil is administrated via targeted infusion control using the Minto model. ANI scores, vital signs, remifentanil infusion rate are collected at predetermined time points according to the protocol from the start to the end of the surgery.

Timeline

Start date
2024-04-23
Primary completion
2025-06-11
Completion
2025-06-11
First posted
2024-05-29
Last updated
2024-05-30

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT06432894. Inclusion in this directory is not an endorsement.